CorMedix Inc. has FDA-approved product DefenCath with positive outlook and potential growth.

From Barchart: 2025-06-24 11:58:00

CorMedix Inc. (CRMD) is a biotech company with a FDA-approved product, DefenCath, designed to prevent catheter-related bloodstream infections. The stock’s trailing and forward P/E ratios are 59.44 and 22.88 respectively. The price was $14.86 as of June 12th.

DefenCath saw a 71% reduction in infections in a clinical trial, leading to FDA approval in November 2023. The drug will begin outpatient rollout in July 2024. CorMedix already has contracts with major dialysis organizations covering 70% of its estimated patient TAM.

CorMedix is preparing for post-TDAPA reimbursement negotiations and is conducting a real-world evidence study to track patient outcomes. DefenCath has regulatory exclusivity through 2033 and no U.S. competitors. Analysts are optimistic about its potential and believe it could become a U.S. standard-of-care.

Archetype Capital is bullish on CorMedix, emphasizing its risk/reward profile, major dialysis contracts, and upcoming real-world evidence study. The stock has appreciated by roughly 33% since previous coverage. While 12 hedge funds held CRMD in Q1, it is not among the 30 most popular stocks among hedge funds.

Read more: CorMedix Inc. (CRMD): A Bull Case Theory